GLG News by Cardiologists who Specialize in Hypertension (US)

Third party payers benefit the most from EHRs because it makes charts easier to audit   The cost of implementing an EHR is excessive for a small practice of 2-5 physicians.

I am a heavy user of ARB's and Tekturna.  This article does not really show anything of significance.  Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...

Novartis was able to show that combining tekturna with HCTZ provided significant improvement in blood pressure and did so safely.  They also showed that it provides better 24 hour coverage and coverage if patients miss a dose or take it late, this is a significant improvement over its competitors...

Patients with rare malignancies, especially those with already metastatic diseases, are being treated with novel oncologic agents.  However, as is being seen with many drugs, the hemodynamic consequences of these agents, in many cases a rise in blood pressure, may lead to cardiovascular consequences. ...

The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal...

Challenges to pharmaceutical patents prior to the "official" expiration of the patent are proliferating; if they are allowed to stand, that is, if the "original" patent is successfully voided one of the crucial financial incentives to novel pharmaceutical research will be abridged and the "profit" motive...

The meta-analysis of the rimonabant trials points to an increase in psychiatric diagnoses. What is missing in this report is the numberical and statistical significance of the findings.  This debate needs more rigor; the type of rigor that is applied to cardiac endpoints, needs to be applied here. ...

The devil is in the details! Far from disappointing, the protocol ammendments (dosing) based on pharmacokinetic analysis that have been effected are both prudent and reassuring. Prasugrel dosing is likely being adjusted to reflect its metabolism in various patient populations including the elderly and...

Ask any patient with diabetes what they want for a therapeutic option and they'll tell you non-injectable insulin.  They understand that all the other medications are a poor substitution for the replacement of pancreatic insulin and they are tired of taking multiple pills each day. So why did...

The failure of drug eluting stents in the eyes of the public and in the medical community is probably not a failure of the device as much as a failure of patient managment.  It is clear that atherothrombotic vascular disease requires a life-long commitment to blood pressure, cholesterol, and blood...